DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration will be participating at the Barcelona 2015 XXXIII Congress of the European Society of Cataract & Refractive Surgeons (ESCRS). ESCRS is Europe’s leading organization for cataract and refractive surgeons and is at the forefront of development in anterior segment surgery. The event will be held the 5th through the 9th of September at Fira Barcelona Gran Via.
The Company will report on the safety and efficacy of the Presbia Flexivue Microlens™, a corneal inlay solution for presbyopia, the age-related loss of near vision. The event will feature presentations and discussions by study authors who are certified Presbia Flexivue Microlens surgeons.
“We are very pleased to have the opportunity to expand the awareness of our Presbia Flexivue Microlens as a safe and effective, and perhaps the best surgical treatment for presbyopia,” said Todd Cooper, President and CEO of Presbia. “We are broadening our commercial reach in key markets in the European Union and Asia, and this event provides the opportunity to present key industry leaders the very positive results of the surgeries supported by clinical metrics and patient feedback.”
Presbia representatives will be available during the conference from Saturday, September 5 through Wednesday, September 8 at Presbia’s booth located at C16 in Hall 7 on the exhibition floor to acquaint surgeons and distributors with Presbia’s products and procedures.
Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens commenced in 2014.